Merck Nears Acquisition of Cidara to Strengthen Flu Prevention Arsenal

Merck is approaching the final stages of a major acquisition of Cidara Therapeutics, positioning itself to expand its influence in the global fight against influenza. The anticipated agreement is expected to include upfront payments combined with future milestone-based compensation, ensuring alignment with clinical and commercial progress.

Central to the deal is Cidara’s promising antiviral candidate, CD388, a long-acting therapy designed to provide broad protection against both influenza A and B. Early trial results have shown extended protection lasting up to 24 weeks, with particularly strong benefits for individuals at high risk of severe illness.

Merck’s leadership views CD388 as a potential long-term growth engine, especially as the world seeks stronger preventive tools for seasonal and pandemic influenza threats. The acquisition reflects Merck’s broader plan to diversify its pipeline and strengthen late-stage assets through targeted strategic deals. With increasing demand for next-generation antiviral solutions, this move signals Merck’s intention to remain at the forefront of infectious disease innovation.